ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis - GlobeNewswire Get link Facebook X Pinterest Email Other Apps December 20, 2019 ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis GlobeNewswire Get link Facebook X Pinterest Email Other Apps Comments
Comments
Post a Comment